Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
Ramat Gan, Israel
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 242% %
Debt-to-equity 402% %
Return On Equity -650% %
Return On Assets -129% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,126,642 shares -68%
Common Stock, Shares, Outstanding 3,126,642 shares -72%
Common Stock, Value, Issued $42,000 USD 4100%
Weighted Average Number of Shares Outstanding, Basic 1,132,658 shares 2521%
Weighted Average Number of Shares Outstanding, Diluted 1,132,658 shares 2521%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,636,000 USD -33%
General and Administrative Expense $4,490,000 USD -76%
Operating Income (Loss) $9,126,000 USD 59%
Nonoperating Income (Expense) $117,000 USD -101%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,243,000 USD 72%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $9,247,000 USD 72%
Earnings Per Share, Basic -81 USD/shares -99%
Earnings Per Share, Diluted -81 USD/shares -99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,243,000 USD 368%
Other Assets, Current $47,000 USD -41%
Assets, Current $11,055,000 USD 263%
Property, Plant and Equipment, Net $26,000 USD -26%
Operating Lease, Right-of-Use Asset $442,000 USD
Assets $11,614,000 USD 276%
Accounts Payable, Current $946,000 USD 18%
Employee-related Liabilities, Current $721,000 USD 4.9%
Liabilities, Current $2,786,000 USD -22%
Operating Lease, Liability, Noncurrent $311,000 USD
Liabilities $4,637,000 USD -40%
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value $0 USD -100%
Retained Earnings (Accumulated Deficit) $50,754,000 USD -22%
Stockholders' Equity Attributable to Parent $6,977,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $6,977,000 USD
Liabilities and Equity $11,614,000 USD 276%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,729,000 USD -7.2%
Net Cash Provided by (Used in) Financing Activities $8,624,000 USD 195%
Net Cash Provided by (Used in) Investing Activities $7,000 USD
Common Stock, Shares Authorized 9,000,000 shares -96%
Common Stock, Shares, Issued 3,126,642 shares -72%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 10000%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9,324,000 USD 361%
Interest Paid, Excluding Capitalized Interest, Operating Activities $40,000 USD
Deferred Tax Assets, Valuation Allowance $6,899,000 USD 25%
Deferred Tax Assets, Gross $7,021,000 USD 26%
Operating Lease, Liability $526,000 USD 208%
Depreciation $1,000 USD -82%
Payments to Acquire Property, Plant, and Equipment $7,000 USD -100%
Lessee, Operating Lease, Liability, to be Paid $636,000 USD
Property, Plant and Equipment, Gross $99,000 USD -26%
Operating Lease, Liability, Current $174,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $167,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $165,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -7.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $110,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $172,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $5,800,000 USD 32%
Lessee, Operating Lease, Liability, to be Paid, Year Four $132,000 USD
Operating Lease, Payments $56,000 USD
Additional Paid in Capital $57,689,000 USD 56%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $96,000 USD -99%